How should I adjust therapy for my type 2 diabetic patient whose A1c rose from 9.3% to 10.3% while on metformin (Glucophage) 500 mg twice daily, insulin glargine 20 U at bedtime, and a sliding‑scale of rapid‑acting insulin (Novolog) with meals?

Immediate Insulin Intensification Required for Rising A1c on Current Regimen

Your patient's A1c has risen from 9.3% to 10.3% despite being on metformin 500 mg twice daily, insulin glargine 20 units at bedtime, and sliding-scale Novolog with meals—this represents treatment failure requiring aggressive basal insulin titration and addition of scheduled prandial insulin, not just correction doses. 1, 2

Critical Assessment of Current Regimen Inadequacy

• The current metformin dose of 500 mg twice daily (1000 mg total) is profoundly subtherapeutic; metformin provides maximal glucose-lowering at 2000 mg daily (1000 mg twice daily), and doses below this leave roughly half of the drug's efficacy untapped. 1

• Insulin glargine 20 units at bedtime for a patient with A1c 10.3% represents severe under-dosing; for adults with A1c ≥10%, guidelines recommend starting doses of 0.3–0.5 units/kg/day as total daily insulin, meaning this patient likely needs 30–50 units/day total (assuming typical adult weight). 1, 2

• Sliding-scale insulin as the sole prandial strategy is explicitly condemned by the American Diabetes Association and all major diabetes societies; only ≈38% of patients achieve mean glucose <140 mg/dL with sliding-scale alone versus ≈68% with scheduled basal-bolus therapy. 1, 2

• The rise in A1c from 9.3% to 10.3% indicates progressive beta-cell failure and worsening insulin resistance that cannot be addressed by reactive correction doses alone. 2, 3

Immediate Medication Adjustments Required

1. Aggressive Basal Insulin Titration (Insulin Glargine)

• Increase insulin glargine by 4 units every 3 days until fasting glucose consistently reaches 80–130 mg/dL; the current 20-unit dose is inadequate for A1c 10.3%. 1, 2

• When fasting glucose is ≥180 mg/dL, increase basal insulin by 4 units every 3 days; if fasting glucose is 140–179 mg/dL, increase by 2 units every 3 days. 1

• Stop basal escalation when the dose approaches 0.5 units/kg/day (approximately 35–50 units for most adults) to avoid "over-basalization"; further glucose control should then be achieved by intensifying prandial insulin. 1, 2

2. Initiate Scheduled Prandial Insulin (Replace Sliding-Scale)

• Discontinue sliding-scale insulin as monotherapy immediately and transition to a scheduled basal-bolus regimen with correction doses as adjunct only. 1, 2

• Begin 4 units of rapid-acting insulin (Novolog) before each of the three largest meals (or use 10% of the current basal dose, which would be 2 units per meal initially, but 4 units is more appropriate given A1c 10.3%). 1, 2

• Administer prandial insulin 0–15 minutes before meals for optimal postprandial control. 1

• Titrate each meal dose by 1–2 units (≈10–15%) every 3 days based on 2-hour postprandial glucose readings, targeting postprandial glucose <180 mg/dL. 1

3. Optimize Metformin Dosing (Foundation Therapy)

• Increase metformin from 500 mg twice daily to 1000 mg twice daily (2000 mg total) to achieve maximal glucose-lowering efficacy; doses above 2000 mg add minimal benefit and increase intolerance. 1, 4

• Metformin reduces total insulin requirements by 20–30% when combined with insulin and provides cardiovascular mortality benefit independent of glucose lowering. 1, 4

• Never discontinue metformin when intensifying insulin therapy unless contraindicated (eGFR <30 mL/min/1.73 m²); it remains foundational therapy throughout intensification. 1, 4

4. Correction Insulin Protocol (Adjunct to Scheduled Doses)

• Add 2 units of Novolog for pre-meal glucose >250 mg/dL and 4 units for glucose >350 mg/dL, in addition to the scheduled prandial dose. 1

• Correction insulin must supplement—not replace—scheduled basal and prandial insulin; relying solely on correction doses perpetuates inadequate control. 1, 2

Monitoring Requirements During Titration

• Daily fasting glucose checks are essential during basal insulin titration to guide dose adjustments. 1

• Measure pre-meal glucose before each meal to calculate correction doses. 1

• Obtain 2-hour postprandial glucose after each meal to assess prandial insulin adequacy and guide titration. 1

• Reassess insulin doses every 3 days while actively titrating. 1

• Re-measure A1c at 3 months after therapy intensification; this is the longest acceptable interval before evaluating effectiveness and avoiding therapeutic inertia. 1

Expected Clinical Outcomes with Proper Intensification

• With appropriately weight-based basal-bolus therapy, ≈68% of patients achieve mean glucose <140 mg/dL versus ≈38% with sliding-scale insulin alone. 1, 2

• A1c reduction of 2–3% (or 3–4% in severe hyperglycemia) is achievable within 3–6 months with intensive insulin titration combined with optimized metformin. 1, 2

• Properly implemented basal-bolus regimens do not increase overall hypoglycemia incidence compared with inadequate sliding-scale approaches. 1, 2

Hypoglycemia Management Protocol

• Treat any glucose <70 mg/dL immediately with 15 g of fast-acting carbohydrate, recheck in 15 minutes, and repeat if needed. 1

• If hypoglycemia occurs without an obvious cause, reduce the implicated insulin dose by 10–20% before the next administration. 1

• Provide comprehensive patient education on hypoglycemia recognition, treatment, proper injection technique, and sick-day management. 1, 2

Critical Pitfalls to Avoid

• Do not continue sliding-scale insulin as the sole prandial regimen when A1c is 10.3%; this reactive approach is condemned by major diabetes guidelines and shown to be ineffective. 1, 2

• Do not delay adding scheduled prandial insulin when A1c exceeds 10%; the level of hyperglycemia mandates both basal and mealtime coverage from the outset. 1, 2

• Do not discontinue metformin during insulin intensification unless contraindicated; omission raises insulin needs by 20–30% and worsens outcomes. 1, 4

• Do not continue escalating basal insulin beyond 0.5–1.0 units/kg/day without addressing postprandial hyperglycemia, as this leads to over-basalization with increased hypoglycemia risk and suboptimal control. 1, 2

• Never use rapid-acting insulin at bedtime as a sole correction dose, as this markedly raises nocturnal hypoglycemia risk. 1

Alternative Consideration: GLP-1 Receptor Agonist Addition

• If after 3 months of optimized basal-bolus insulin plus metformin the A1c remains >7%, add a GLP-1 receptor agonist (e.g., semaglutide, dulaglutide) rather than further insulin intensification. 1, 4

• GLP-1 receptor agonists provide an additional 0.6–0.8% A1c reduction when combined with insulin, promote 2–5 kg weight loss (counteracting insulin-associated weight gain), and carry minimal hypoglycemia risk when sulfonylureas are discontinued. 1, 4

• The basal-insulin + GLP-1 RA combination delivers potent glucose-lowering effects with less weight gain and hypoglycemia than intensified basal-bolus regimens alone. 1, 4